Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Goadsby

Showing results (731-740 of 916) with videos related to

Pageof 92
Sort By:
Brain Research|May 25, 2005
Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the catYolande E Knight, John D Classey, Michele P Lasalandra, et al.
Neurology|September 11, 2020
Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized studyPeter J Goadsby, Stephen D Silberstein, Paul P Yeung, et al.
The New England Journal of Medicine|August 18, 2021
Atogepant for the Preventive Treatment of MigraineJessica Ailani, Richard B Lipton, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
The Lancet. Neurology|December 16, 2014
Site of effect of LY2951742 for migraine prophylaxis--authors' replyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Lancet (London, England)|September 28, 1991
Oral sumatriptan in acute migraineP J Goadsby, A S Zagami, G A Donnan, et al.
The Lancet. Neurology|August 16, 2014
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Pain Management|May 16, 2025
Rimegepant orally disintegrating tablet for acute treatment of migraine: a plain language summary of a clinical studyRobert Croop, Peter J Goadsby, David A Stock, et al.
The Journal of Headache and Pain|January 30, 2017
O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided studyMichele Viana, Mattias Linde, Grazia Sances, et al.
Neurobiology of Disease|December 3, 2014
Evidence for orexinergic mechanisms in migraineJan Hoffmann, Weera Supronsinchai, Simon Akerman, et al.
Pageof 92

Showing results (731-740 of 916) with videos related to

Sort By:
Pageof 92
Brain Research|May 25, 2005
Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the catYolande E Knight, John D Classey, Michele P Lasalandra, et al.
Neurology|September 11, 2020
Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized studyPeter J Goadsby, Stephen D Silberstein, Paul P Yeung, et al.
The New England Journal of Medicine|August 18, 2021
Atogepant for the Preventive Treatment of MigraineJessica Ailani, Richard B Lipton, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trialDavid W Dodick, Richard B Lipton, Stephen Silberstein, et al.
The Lancet. Neurology|December 16, 2014
Site of effect of LY2951742 for migraine prophylaxis--authors' replyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Lancet (London, England)|September 28, 1991
Oral sumatriptan in acute migraineP J Goadsby, A S Zagami, G A Donnan, et al.
The Lancet. Neurology|August 16, 2014
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled studyDavid W Dodick, Peter J Goadsby, Egilius L H Spierings, et al.
Pain Management|May 16, 2025
Rimegepant orally disintegrating tablet for acute treatment of migraine: a plain language summary of a clinical studyRobert Croop, Peter J Goadsby, David A Stock, et al.
The Journal of Headache and Pain|January 30, 2017
O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided studyMichele Viana, Mattias Linde, Grazia Sances, et al.
Neurobiology of Disease|December 3, 2014
Evidence for orexinergic mechanisms in migraineJan Hoffmann, Weera Supronsinchai, Simon Akerman, et al.
Pageof 92